Aim: Renal cell carcinoma (RCC) is the seventh commonest cancer in the UK, where first-line (1L) sunitinib and second-line (2L) axitinib are treatment options.Methods: Retrospective, non-interventional data from the Christie NHS Foundation Trust (Manchester, UK). The primary end point was median progression-free survival (mPFS).Results: For 1L sunitinib (n = 622) and 2L axitinib (n = 121), mPFS (95% CI) was 8.4 (7.6, 9.9) and 6.2 (4.9, 9.3) months, respectively. In 1L, Karnofsky performance status, lactate dehydrogenase (LDH), neutrophils, hemoglobin, time from diagnosis to treatment and age were predictors (p < 0.05) of PFS. In 2L, LDH and platelets were predictors of PFS (p < 0.05).Conclusion: Sunitinib and axitinib were effective treatments for RCC. PFS predictors varied between 1L and 2L; LDH was a predictor for both.Clinical Trial Registration: NCT04033991 (ClinicalTrials.gov).
[Box: see text].
Future oncology (London, England). 2024 Oct 09 [Epub ahead of print]
Tom Waddell, Manon Pillai, Kate Armitage, Donna M Graham, Michael Moran, Maria Dilleen, Sinead Holmes, Ewa Śleszyńska-Dopiera, Robert Hawkins
Christie NHS Founsdation Trust, Medical Oncology, Manchester, UK., Pfizer GmbH, Linkstraße 10, Berlin, 10785, Germany., Pfizer, Global Product Development, Sandwich, UK., Pfizer Oncology, Surrey, UK., Quanticate, Warsaw, Poland.